DFine's radiofrequency ablation system gets FDA nod
This article was originally published in Clinica
Executive Summary
A new percutaneous radiofrequency ablation system developed by DFine has received 510(k) approval from the US FDA. The product is intended for the palliative treatment of cancer patients with spinal metastases. These lesions affect over 400,000 patients per year worldwide, causing severe pain and discomfort. Current treatments include narcotics and external beam radiation, which can take "weeks or months" to work, according to DFine. Patients may also need to stop receiving chemotherapy for their primary cancer because of cumulative toxicity. Targeted radiofrequency ablation can provide immediate pain relief, improving patients' quality of life, the San Jose, California-based firm says. The technique is also used to treat liver, lung and kidney cancers, using heat produced by radio waves to destroy cancer cells.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.